Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

181.14 +4.08 (+2.30%)
Official Closing Price Updated: 7:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
71 72 Next >
Assessing AbbVie's Performance Against Competitors In Biotechnology Industry
Via Benzinga
Tuesday Talk: Big-Tech Under Attack
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs. 
Via Talk Markets
Biotechnology And Healthcare, A Bit Of A Lull
Strong momentum of Tech and Chip stocks may be too good of a distraction for biotech investors. 
Via Talk Markets
Nasdaq Turns Higher; Akanda Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Landos Biopharma (LABP) Stock Up 168% Today?
Landos Biopharma stock is up on Monday as LABP investors learn about a massive acquisition deal with AbbVie that values it at $137.5 million. 
Via InvestorPlace
The Latest Analyst Ratings For AbbVie
Via Benzinga
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
Via Benzinga
Decoding AbbVie's Options Activity: What's the Big Picture?
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
Crude Oil Moves Higher; US New Home Sales Fall In February
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
From Brodsky & Smith LLC
Via GlobeNewswire
US Stocks Down; Chicago Fed National Activity Index Rises In February
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. 
Via Talk Markets
Healthcare And Biotech Update With Market At 2024 Highs
The bull market is intact with technology Stocks dominating, but XLV is up 6.89%YTD. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Top Dividend Stocks to Buy Hand Over Fist
Every company faces headwinds eventually. The top ones know how to bounce back. 
Via The Motley Fool
How Much a $1 Million Portfolio Would Pay in Dividends
See how to construct a $1 million portfolio. 
Via The Motley Fool
SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster
With over 100 dividend growth stocks in its portfolio, the SCHD ETF has proved to be a formidable income-generating vehicle for investors. 
Via InvestorPlace
Topics ETFs
3 Must-Have Dividend Kings for a Steady Income Stream
Discover the dividend kings with constant growth, dominating pharmaceuticals, household products and biotechnology industries. 
Via InvestorPlace
Trouble-Proof Dividend Darlings: 7 Stocks That Keep Paying No Matter What
With economic conditions presenting a question mark for the consumer economy, these dividend stocks may shine brightly. 
Via InvestorPlace
Topics Economy
Exposures Economy
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
The company tested its psoriatic arthritis drug over 24 weeks against Humira. 
Via Investor's Business Daily
Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?
Results with MoonLake Immunotherapeutics' Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors. 
Via Benzinga
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
There are some great companies at attractive prices in the lucrative pharmaceutical space. 
Via The Motley Fool
3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market. 
Via InvestorPlace
The AI Race Gets Litigious
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
These businesses can pack a punch in your portfolio over the long run. 
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.